Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

MilliporeSigma™ Calbiochem™ Nicotinamide Phosphoribosyltransferase Inhibitor, FK866

The Nicotinamide Phosphoribosyltransferase Inhibitor, FK866, also referenced under CAS 658084-64-1, controls the biological activity of Nicotinamide Phosphoribosyltransferase. This small molecule/inhibitor is primarily used for Neuroscience applications.

Manufacturer:  MilliporeSigma™ 4819082MG

Catalog No. 48-190-82MG


Add to cart

Description

Description

A cell-permeable pyridinylacrylamide compound that acts as a selective, allosteric NAPRT/NAMPT (nicotinamide phosphoribosyltransferase) inhibitor (Ki = 0.4nM for the enzyme/substrate complex; Ki ft. = 0.3nM for the free enzyme), while exhibiting no effect toward NPRT (nicotinic acid phosphoribosyltransferase) activity (82% inhibition of NAPRT activity at 10nM vs no inhibition of NPRT activity at 1µM in K-562 extract). FK866 treatment is shown to induce cell death by depleting NAD+ (Cat. Nos. 481911 and 481915) in HepG2 and NIH-3T3 cultures (by >95% after 24 h treatment of 10nM FK866), likewise the addition of exogenous NAD+ is demonstrated to rescue NIH-3T3 and SH-SY5Y from FK866-induced NAD+-depletion and cell death.
Specifications

Specifications

Supplied as a 50 mM (2mg/102.17μl) solution in DMSO.
Yellow liquid
2mg
C24H29N3O2
DMSO
97% by HPLC
Protect from Light
658084-64-1
391.5g/mol
Documents
Provide Content Correction

We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Cancel Submit